Telaprevir
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 315233

CAS#: 402957-28-2

Description: Telaprevir (VX-950), marketed under the brand names Incivek and Incivo, is a pharmaceutical drug for the treatment of hepatitis C co-developed by Vertex Pharmaceuticals and Johnson & Johnson. It is a member of a class of antiviral drugs known as protease inhibitors. Specifically, telaprevir inhibits the hepatitis C viral enzyme NS3.4A serine protease. Telaprevir is only indicated for use against hepatitis C genotype 1 viral infections and has not been proven to have an effect on or being safe when used for other genotypes of the virus. The standard therapy of pegylated interferon and ribavirin is less effective on genotype 1.


Price and Availability

Size
Price

5mg
USD 190
Size
Price

10mg
USD 350
Size
Price

25mg
USD 750

Telaprevir, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 315233
Name: Telaprevir
CAS#: 402957-28-2
Chemical Formula: C36H53N7O6
Exact Mass: 679.40573
Molecular Weight: 679.85
Elemental Analysis: C, 63.60; H, 7.86; N, 14.42; O, 14.12


Synonym: VX950; VX950; VX 950; Incivek; Incivo

IUPAC/Chemical Name: (3S,3aS,6aR)-2-[(2S)-2-[[(2S)-2-cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide

InChi Key: BBAWEDCPNXPBQM-GDEBMMAJSA-N

InChi Code: InChI=1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30+/m0/s1

SMILES Code: O=C([C@@H]1[C@](CCC2)([H])[C@]2([H])CN1C([C@@H](NC([C@H](C3CCCCC3)NC(C4=NC=CN=C4)=O)=O)C(C)(C)C)=O)N[C@@H](CCC)C(C(NC5CC5)=O)=O


Technical Data

Appearance:
solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Goralczyk AD, Cameron S, Amanzada A. Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and -experienced patients. BMC Gastroenterol. 2013 Oct 14;13:148. doi: 10.1186/1471-230X-13-148. Review. PubMed PMID: 24118976; PubMed Central PMCID: PMC3852825.

2: Schmutz JL, Trechot P. [Telaprevir-induced pityriasis rubra pilaris]. Ann Dermatol Venereol. 2013 May;140(5):414-5. doi: 10.1016/j.annder.2013.01.336. Epub 2013 Mar 6. Review. French. PubMed PMID: 23663723.

3: Kiang TK, Wilby KJ, Ensom MH. Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions. Clin Pharmacokinet. 2013 Jul;52(7):487-510. doi: 10.1007/s40262-013-0053-x. Review. PubMed PMID: 23553423.

4: Rajani AK, Ravindra BK, Dkhar SA. Telaprevir: changing the standard of care of chronic hepatitis C. J Postgrad Med. 2013 Jan-Mar;59(1):42-7. doi: 10.4103/0022-3859.109493. Review. PubMed PMID: 23525057.

5: Izquierdo-García E, Escobar-Rodríguez I. [Systematic review of new protease inhibitors interactions: telaprevir and boceprevir]. Farm Hosp. 2012 Nov-Dec;36(6):469-82. doi: 10.7399/FH.2012.36.6.47. Review. Spanish. PubMed PMID: 23461440.

6: Gu L, Chen Q, Xie J, Yan Y, Wu G, Tan J, Liang B, Chen W, Wu P, Su L, Tang N. Telaprevir for genotype 1 chronic hepatitis C: a systematic review and meta-analysis. Pharmazie. 2012 Dec;67(12):963-72. Review. PubMed PMID: 23346756.

7: van Heeswijk RP, Beumont M, Kauffman RS, Garg V. Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther. 2013;18(4):553-60. doi: 10.3851/IMP2527. Epub 2013 Jan 23. Review. PubMed PMID: 23344266.

8: Jesudian AB, Jacobson IM. Optimal treatment with telaprevir for chronic HCV infection. Liver Int. 2013 Feb;33 Suppl 1:3-13. doi: 10.1111/liv.12079. Review. PubMed PMID: 23286840.

9: Nikitin IG, Gogova LM, Baikova IE, Kislyakov VA, Volynkina VM. [Telaprevir: new possibilities for antiviral treatment in patients with chronic hepatitis C]. Ter Arkh. 2012;84(11):75-80. Review. Russian. PubMed PMID: 23252254.

10: Esteban R, Buti M. Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients. Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):445-53. doi: 10.1016/j.bpg.2012.09.001. Review. PubMed PMID: 23199503.